Mizuho reissued their buy rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Wednesday morning. The firm currently has a $29.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the company. Canaccord Genuity set a $22.00 target price on Alder Biopharmaceuticals and gave the stock a buy rating in a report on Friday, January 12th. Zacks Investment Research downgraded Alder Biopharmaceuticals from a hold rating to a sell rating in a report on Thursday, January 11th. BMO Capital Markets boosted their target price on Alder Biopharmaceuticals to $26.00 and gave the stock an outperform rating in a report on Tuesday, January 9th. ValuEngine raised Alder Biopharmaceuticals from a strong sell rating to a sell rating in a report on Thursday, January 4th. Finally, BidaskClub raised Alder Biopharmaceuticals from a sell rating to a hold rating in a report on Thursday, January 4th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. Alder Biopharmaceuticals has a consensus rating of Buy and a consensus target price of $27.93.

Shares of Alder Biopharmaceuticals (NASDAQ:ALDR) opened at $13.75 on Wednesday. Alder Biopharmaceuticals has a 12 month low of $8.60 and a 12 month high of $25.45. The firm has a market capitalization of $901.56, a P/E ratio of -2.56 and a beta of 2.60.

Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.21) by $0.29. During the same period in the prior year, the business earned ($0.70) earnings per share. equities analysts expect that Alder Biopharmaceuticals will post -5.14 EPS for the current year.

In other Alder Biopharmaceuticals news, insider Mark James Litton sold 16,519 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $10.80, for a total transaction of $178,405.20. Following the transaction, the insider now owns 116,451 shares of the company’s stock, valued at approximately $1,257,670.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 10.60% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the business. Redmile Group LLC lifted its holdings in Alder Biopharmaceuticals by 16.4% during the 2nd quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock worth $25,463,000 after buying an additional 313,925 shares in the last quarter. Pinnacle Associates Ltd. acquired a new position in Alder Biopharmaceuticals during the 3rd quarter worth $14,823,000. Asymmetry Capital Management L.P. lifted its holdings in Alder Biopharmaceuticals by 320.1% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 166,752 shares of the biopharmaceutical company’s stock worth $1,909,000 after buying an additional 127,056 shares in the last quarter. Citigroup Inc. lifted its holdings in Alder Biopharmaceuticals by 285.7% during the 2nd quarter. Citigroup Inc. now owns 33,433 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 24,765 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Alder Biopharmaceuticals by 3,084.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 235,603 shares of the biopharmaceutical company’s stock worth $2,697,000 after buying an additional 228,205 shares in the last quarter. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Alder Biopharmaceuticals (ALDR) Given Buy Rating at Mizuho” was posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/02/03/alder-biopharmaceuticals-aldr-given-buy-rating-at-mizuho.html.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.